# Interpace Biosciences, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Interpace Biosciences, Inc.). ## Overview Interpace Biosciences, Inc. is a U.S.-based clinical diagnostics company that develops and performs proprietary molecular tests used to support cancer-related decision-making, with a focus on pancreatic and other oncology-related conditions. The company generates revenue primarily from clinical services billed to third-party payers and Medicare, and its business model is tightly linked to reimbursement coverage and laboratory test volumes. ## Products & services • Proprietary molecular clinical diagnostic tests • PancraGEN® pancreatic cancer risk assessment test • First-line fluid chemistry testing • Laboratory-based clinical services and result reporting • Reimbursement-billed testing for third-party payers and Medicare - **Clinical diagnostic testing** (100%) — Proprietary laboratory assays and molecular tests performed on patient specimens. - Proprietary molecular clinical diagnostic tests - PancraGEN® pancreatic cancer risk assessment test - First-line fluid chemistry testing - Laboratory-based clinical services and result reporting - Reimbursement-billed testing for third-party payers and Medicare ## Customers The company sells its clinical services into the healthcare reimbursement system, so its direct customers are largely physicians, hospitals, and other ordering providers that submit patient specimens for testing. Payment is typically collected from Medicare, commercial insurers, and other third-party payers, making reimbursement policy a central driver of demand and revenue realization. - **Ordering physicians and specialists** (primary) — They order proprietary tests to support diagnosis and treatment decisions, especially in oncology and pancreatic disease. - **Medicare beneficiaries** (primary) — A key payer base for PancraGEN® and related testing; reimbursement coverage directly determines whether the test can be offered. - **Commercial insurers and third-party payers** (primary) — They reimburse clinical services and affect realized revenue through coverage policies and collection rates. - **Hospitals and outpatient clinics** (secondary) — They submit specimens and rely on the company’s lab results to support patient management. - Physicians and specialists ordering oncology-related diagnostic tests - Hospitals and clinics sending patient specimens for lab analysis - Medicare patients, especially for PancraGEN®-related testing - Commercial insurers and other third-party payers reimbursing tests - Direct-bill payers and healthcare providers using proprietary assays ## Geography Interpace Biosciences operates as a U.S.-centric diagnostics business, with revenue driven by domestic clinical testing and U.S. reimbursement systems. The company’s exposure is concentrated in the United States because Medicare coverage decisions and U.S. laboratory regulations directly affect whether its tests can be marketed and reimbursed. - Revenue is primarily generated in the United States - Medicare policy changes directly affect test availability and demand - U.S. laboratory regulation and LDT oversight are key operating constraints - Domestic payer mix drives collection rates and revenue recognition - No meaningful international operating footprint was disclosed ## Strategy Management is focused on preserving liquidity, improving margins, and resizing the cost base after the loss of Medicare reimbursement for PancraGEN®. The company is also pursuing strategic alternatives and financing options, while considering an uplisting to Nasdaq to improve access to capital. - **Restructure the cost base** (short-term) — The loss of PancraGEN® reimbursement requires a smaller operating footprint to preserve profitability and cash. - **Maintain liquidity** (short-term) — The company needs sufficient cash to fund operations while reimbursement and revenue visibility remain uncertain. - **Replace lost test revenue** (medium-term) — Future growth depends on sustaining clinical service revenue and developing new molecular solutions. - Reduce costs and align workforce with lower PancraGEN® demand - Protect liquidity through cash management and receivables collection - Improve margins through operating discipline and expense containment - Seek financing, alliances, or strategic alternatives for flexibility - Explore a Nasdaq uplisting to broaden capital access ## Risks The most important company-specific risk is reimbursement dependence: CMS ended coverage for PancraGEN®, which materially reduces the company’s ability to sell that test and pressures revenue. The company also faces liquidity and refinancing risk because it has a secured lender with foreclosure rights and limited access to capital after its Nasdaq delisting, alongside typical diagnostics risks such as regulatory change, payer mix volatility, and third-party supply dependence. - **Loss of Medicare reimbursement for PancraGEN®** [critical] — The company states it cannot continue offering the test after CMS ended coverage, removing a core product from its portfolio. - **Liquidity and refinancing pressure** [high] — The company relies on cash, collections, and external financing, but capital access is limited after delisting. - **Secured lender foreclosure rights** [high] — If obligations are not repaid on time, substantially all assets could be foreclosed upon. - **Regulatory and reimbursement change** [high] — LDT oversight, payer coverage, and pricing rules can alter whether tests are reimbursed profitably. - **Third-party supply dependence** [medium] — The company depends on external suppliers for materials used in testing, which can affect service continuity. - CMS reimbursement loss for PancraGEN® can eliminate a key revenue stream - Secured lender foreclosure rights create balance-sheet and liquidity risk - Access to capital is constrained after Nasdaq delisting - LDT regulation and pricing rules can change test economics quickly - Revenue depends on payer collections and historical reimbursement rates - Third-party supply dependence can disrupt lab operations ## Accounting Revenue is recognized when test results are completed and released, but the amount recorded depends on estimated net realizable value based on historical collection rates by payer category. That makes reimbursement estimates, contractual allowances, and payer mix especially important to quarterly results, while labor, supplies, and facility costs drive cost of revenue. The company also highlights leases, income taxes, and stock-based compensation as critical accounting policies, and it records restructuring and severance charges as the workforce reduction is implemented. - **Revenue recognition and net realizable value estimates** — Can shift revenue and gross margin between periods - **Contractual allowances and payer mix** — Affects net revenue and receivables valuation - **Restructuring and severance accruals** — Impacts operating expenses and cash outflows - **Stock-based compensation** — Affects operating income and adjusted EBITDA reconciliation - Revenue recognition depends on estimated collections by payer category - Contractual allowances and NRV estimates can move reported revenue - Test volume changes affect lab supply costs and gross margin - Restructuring and severance charges will hit 2025 operating results - Leases, income taxes, and stock-based compensation are key estimates --- *Last updated: 2026-04-28T20:16:27.776646+00:00*